Coya Therapeutics
COYA
21 hedge funds and large institutions have $20.6M invested in Coya Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 0 closing their positions.
279% more capital invested
Capital invested by funds: $5.45M → $20.6M (+$15.2M)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
40% more funds holding
Funds holding: 15 → 21 (+6)
13.9% more ownership
Funds ownership: 14.24% → 28.14% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Greenlight Capital
New York
|
+$4.47M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.75M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
| 4 |
PCM
Potomac Capital Management
New York
|
+$117K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$229K |
| 2 |
BlackRock
New York
|
-$1.35K |
| 3 |
Morgan Stanley
New York
|
-$6 |
COYA Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Coya Therapeutics (COYA) for Q4 2023, worth a combined $20.6M — up 279% from $5.45M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new COYA positions and 0 closed out — a net gain of 6 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Greenlight Capital, adding an estimated $4.47M. The largest seller was Worth Venture Partners, cutting an estimated $229K.
- 21 institutional investors held Coya Therapeutics (COYA) as of Q4 2023, up from 15 in Q3 2023.
- Funds reported $20.6M of Coya Therapeutics stock for Q4 2023, up 279% quarter-over-quarter.
- 6 funds opened new Coya Therapeutics positions in Q4 2023 and 0 closed out, a net change of +6 holders.
- The largest Coya Therapeutics buyer in Q4 2023 was Greenlight Capital, an estimated $4.47M added.
- The largest Coya Therapeutics seller in Q4 2023 was Worth Venture Partners, an estimated $229K sold.
Based on aggregated 13F filings for Q4 2023.